MedPath

STELLENBOSCH UNIVERSITY

🇿🇦South Africa
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

24

Active:3
Completed:9

Trial Phases

3 Phases

Phase 1:5
Phase 3:3
Not Applicable:15

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials

Not Applicable
15 (65.2%)
Phase 1
5 (21.7%)
Phase 3
3 (13.0%)
No trials found

News

DiaMedica's DM199 Shows Promising Blood Pressure Reduction in Phase 2 Preeclampsia Trial

DiaMedica Therapeutics reported positive interim Phase 2 results for DM199 (rinvecalinase alfa) in treating preeclampsia, showing statistically significant reductions in both systolic and diastolic blood pressure.

First Clinical Trial of DM199 Launched to Combat Preeclampsia

Stellenbosch University initiates a clinical trial for DM199, a novel drug targeting the root cause of preeclampsia, a severe pregnancy complication.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.